Category Archives: Stocks

Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

covid 19

March 17, 2020 – Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic. 

Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging emergency results. Vitro Biopharma has the highest level of umbilical cord stem cell technology to reduce death rates due to the Coronavirus pandemic.

https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese- patient-saved-stem-cell

https://www.dailytargum.com/article/2020/03/commentary-compassionate-use-of-stem-cell- therapy-to-treat-severe-covid-19-could-save-lives-now

http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml

Dr. Jim Musick, Ph.D., CEO said, “As the world struggles to deal with the COVID-19 pandemic, it is important to consider stem cell therapy to reduce death rates. This is supported by clinical studies and clinical trials are underway to substantiate safety and efficacy. Vitro Biopharma is ideally suited to provide high quality stem cells to US patients, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our umbilical cord AlloRx™ Stem Cells and stem cell growth media MSC-Gro™ have been used in the treatment of hundreds of patients without adverse events and show efficacy in treatment of COPD, osteoarthritis, multiple sclerosis and Alzheimer’s disease.

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx™ Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands www.DVCStem.com.

Vitro Biopharma has a patent-pending, proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients. Our stem cells have been shown to be safe in Phase I protocols as we also gain evidence of efficacy.

We are in contact with federal, state and local governments to inform them of our AlloRx ™ Stem Cell therapy option for Coronavirus infections.. The pandemic deserves consideration of all therapeutic options and there is evidence that stem cell therapy reduces the death rate from Coronavirus COVID-19 infections. We believe that critically ill patients should have the right to try stem cell therapy in the United States.”

CONTACT:
Dr. James Musick Chief Executive Officer
Vitro Biopharma (303) 550-2778
E-mail: jim@vitrobiopharma.com
Source: Vitro Diagnostics, Inc

Forward-Looking Statements
Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,”
“anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.

Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.

Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

MRI Interventions Reports 52% Increase in First Quarter Revenue

MRI Interventions logo

Record $2.5 million quarterly revenue driven by growth across entire portfolio OTCQB: MRIC) (the “Company”) today announced financial results for its first fiscal quarter ended March 31, 2019.

First Quarter 2019 Highlights

  • Increased first quarter revenue 52% year-over-year to $2.5 million.
  • Reported $1.6 million in quarterly functional neurosurgery revenue, an increase of 38% over the prior year first quarter.
  • Reported biologics and drug delivery revenue of $382,000, an increase of 93% over the prior year, including first European shipments to Lysogene for use in their P4-SAF-302 trial.
  • Reported capital sales and other services revenue of $486,000, which includes two system sales; the systems sales, combined with three evaluation installations, bring total U.S. installed base to 63 systems.
  • Completed 175 procedures across the Company’s product portfolio.
  • Completed the transfer of the V-Tag 510(k) from Voyager Therapeutics, Inc. and completed initial clinical builds.
  • Generated gross margin of 64%.
  • Maintained reduction of cash used in operations to $609,000, which included annual bonus compensation and semi-annual interest payment.

Resurrection of Emergent Health Corp. (EMGE: OTC Markets)

JDI Life logo

Emergent Health Corp. (the “Company”) purpose is to update shareholders:

  1. The Company had a loss of $900,000 under a FL management team from 2015 to early 2017. This has now become a loss carry forward.
  2. New management has taken control of the Company and revenue and a small profit was produced in 2018. Though the results may be considered nominal at this time, it is believed to be a snapshot of the future.
  3. The Company has the intention to become a holding company and build value on the basis of Book Value, profit and rate of growth.
  4. The Company is in process of launching a network marketing division http://jdi.jdilife.com The plan is to build this division to the point of supporting it as a public company subsidiary of the Company.
  5. The Company intends to form a Medical Food company, which it too intends to have become a public company subsidiary of the Company. The intended initial product has Intellectual Property protection.
  6. The company intends to diligently work towards current status on OTC Markets.
  7. From time to time, management on behalf of the Company, may purchase Company shares in the open market with the intention to retire those shares to the Company Treasury.

MTrac Emerging as the FinTech Provider of Choice is Poised for Exponential Revenue Growth in 2019

Global-Payout-logo

Global Payout Inc. (OTCPINK: GOHE) (“Global”) and its wholly-owned subsidiary MTrac Tech Corporation (“MTrac”) are pleased to announce that transactional data and revenue into Q1 of 2019 highlights the continued growth, adaptation, and overall benefit to the one-of-kind MTrac Payment Solution.

As has been the trend since the current iteration of the MTrac system was deployed back in October, totals associated with daily and monthly sales and transactional volume along with the average ticket cost processed within the system continue to climb each month at what the Company perceives to be a very steady and encouraging pace, and the first quarter is seeing a continuation of this very positive trend. 

OTC Markets Lists Securities of Fuse Medical, Inc. as Exempt from Penny Stock Designation

Fuse Medical logo

Fuse Medical, Inc., (OTC PINK: FZMD), (“Fuse” or the “Company”), announced that OTC Markets has identified Fuse as “Penny Stock Exempt,” meaning that shares of Fuse’s common stock, par value $0.01 per share (the “Common Stock”), is no longer a “Penny Stock” as defined in Rule 3a51-1, promulgated under the Securities Exchange Act of 1934, as amended.

To qualify as “Penny Stock Exempt” on the OTC Markets, an issuer must satisfy one of the following requirements: (i) the issuer’s securities have a minimum price greater than $5 per share; (ii) the issuer has average revenues of at least $6 million for the last three (3) years; or (iii) the issuer has net tangible assets exceeding $2 million, if the issuer has been in continuous operations for at least three (3) years or $5 million if less than three (3) years.